Feb 13, 2025 / 02:00PM GMT
Aamir Mahmood - Acarix AB - President, Chief Executive Officer
Thank you all for joining the Q4 2024 earnings call of Acarix. I appreciate you all joining, and the support we've received.
Just to kind of kick it off, I want to make sure that we're able to identify who we are and what we do for any new shareholders or analysts that are following us. So CADScor system by Carrick is truly transforming early cardiac diagnostics. We are able to present an opportunity at point of care to rule out CAD with a 96.2 negative predictive value.
Within 4 to 6 minutes, upwards to 10 minutes max. We are an FDA approved de novo device, so meaning first in class. We're also CE marked. We have over 15 years of R&D within the car and 45 patents. We've had clinical trials with 6,000 plus patients and over 40,000 assessments done to date.
As I mentioned, we are, FDA approved and CE mark, organization and product. We're based in Sweden, Stockholm, and we have most of our R&D and manufacturing in Denmark. Our acute focus on sales is in the US, which is the world's largest market and
Q4 2024 Acarix AB Earnings Call Transcript
Feb 13, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers